CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 506 enrolled
Drug / intervention
Aliskiren +3 moredrug
Likely dose
Aliskiren 150 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01042392
NCT01042392Phase 4Completed
CompareCT.gov

Efficacy of Aliskiren Compared to Ramipril in the Treatment of Moderate Systolic Hypertensive Patients

Novartis·interventional·Posted Jan 5, 2010·Updated Apr 3, 2012

In Brief

A Phase 4 clinical trial evaluating Aliskiren, Ramipril, and 2 other interventions for Essential Hypertension. Completed, enrolled 506 participants across 98 sites.

Detailed Summary

This prospective multicenter, double blind study will evaluate the efficacy and safety of aliskiren versus ramipril in patients with moderate systolic essential hypertension.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEssential Hypertension
CountriesFrance
Collaborators--

Timeline

Phase 4CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedJan 5, 2010
Enrollment StartNov 1, 2009
Primary CompletionJan 1, 2011
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 16.5 years ago

Interventions

Aliskirendrug

150 mg Aliskiren as film-coated tablet

Ramiprildrug

Ramipril 5 mg was given in capsule form.

Matching placebo to Aliskirendrug

The tablet of matching placebo to aliskiren 150 mg for period I and III. In period II, matching placebo to Aliskiren was given to Ramipril active treatment arm.

Matching placebo to Ramiprildrug

The placebo capsule to ramipril 5 mg for period I and III. In period II, matching placebo to Ramipril was given to Aliskiren active treatment arm.